Morgan Stanley Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price upped by Morgan Stanley from $314.00 to $319.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Morgan Stanley‘s target price suggests a potential upside of 37.57% from the company’s previous close.

A number of other analysts also recently issued reports on the stock. Weiss Ratings downgraded shares of Jazz Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, October 28th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a research report on Wednesday, August 26th. Piper Sandler raised their target price on shares of Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Stifel Nicolaus set a $275.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, August 4th. Finally, TD Cowen boosted their price target on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $292.95.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ traded up $17.45 during midday trading on Tuesday, reaching $231.88. 647,883 shares of the stock were exchanged, compared to its average volume of 929,876. Jazz Pharmaceuticals has a twelve month low of $128.80 and a twelve month high of $266.38. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. The company has a market cap of $15.05 billion, a P/E ratio of 16.02, a PEG ratio of 0.41 and a beta of 0.38. The stock’s 50 day simple moving average is $231.16 and its 200 day simple moving average is $216.50.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.05) by $0.17. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter in the previous year, the business posted $8.13 earnings per share. Jazz Pharmaceuticals’s quarterly revenue was up 10.4% on a year-over-year basis. On average, sell-side analysts expect that Jazz Pharmaceuticals will post 10.87 earnings per share for the current year.

Insider Activity

In other Jazz Pharmaceuticals news, Director Bruce Cozadd sold 6,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $250.13, for a total transaction of $1,500,780.00. Following the completion of the transaction, the director directly owned 351,875 shares in the company, valued at $88,014,493.75. The trade was a 1.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of the firm’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the completion of the sale, the executive vice president directly owned 65,686 shares in the company, valued at $16,401,794.20. This trade represents a 53.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 94,121 shares of company stock valued at $23,337,922 in the last 90 days. 4.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Triumph Capital Management boosted its position in shares of Jazz Pharmaceuticals by 2.0% during the second quarter. Triumph Capital Management now owns 2,597 shares of the specialty pharmaceutical company’s stock valued at $626,000 after buying an additional 52 shares during the last quarter. XML Financial LLC grew its holdings in Jazz Pharmaceuticals by 1.1% during the third quarter. XML Financial LLC now owns 6,559 shares of the specialty pharmaceutical company’s stock worth $1,519,000 after buying an additional 71 shares in the last quarter. Bessemer Group Inc. raised its position in Jazz Pharmaceuticals by 0.3% in the 1st quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock valued at $4,228,000 after buying an additional 73 shares during the last quarter. Root Financial Partners LLC raised its position in Jazz Pharmaceuticals by 42.8% in the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock valued at $56,000 after buying an additional 89 shares during the last quarter. Finally, Evergreen Capital Management LLC lifted its stake in Jazz Pharmaceuticals by 4.2% during the 3rd quarter. Evergreen Capital Management LLC now owns 2,250 shares of the specialty pharmaceutical company’s stock valued at $521,000 after acquiring an additional 90 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Key Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Raised 2026 guidance: Jazz now expects approximately $4.8 billion-$4.9 billion in full-year revenue, above the roughly $4.7 billion analyst consensus. The company cited sustained commercial execution and expects the Ziihera launch to support growth. Jazz Pharmaceuticals 2026 revenue guidance
• Positive Sentiment: Q3 beat expectations: Jazz reported quarterly revenue of $1.24 billion, up 10.4% year over year and ahead of the $1.21 billion consensus. Its adjusted loss of $3.88 per share was narrower than the expected $4.05 loss. Xywav revenue grew 12%, with 425 net patient additions during the quarter. Jazz Pharmaceuticals third-quarter 2026 results
• Positive Sentiment: Analyst optimism: Royal Bank of Canada raised its price target to $305 and retained an “outperform” rating, while Barclays increased its target to $275 and maintained an “overweight” rating. The revisions reinforce expectations for additional upside. Royal Bank of Canada Jazz Pharmaceuticals rating
• Neutral Sentiment: Jazz launched Ziihera in first-line HER2-positive metastatic gastroesophageal adenocarcinoma and says the product could eventually reach $3 billion-$5 billion in peak sales. The company also completed its Actio acquisition, adding the ABS-1230 epilepsy candidate.
• Neutral Sentiment: Jazz will present Phase 3 ACTION trial and other neuro-oncology data at the Society for Neuro-Oncology meeting later this month, creating a potential near-term catalyst but with clinical-outcome uncertainty. Jazz Pharmaceuticals neuro-oncology research
• Negative Sentiment: The quarterly loss compares with $8.13 in earnings per share a year earlier, while some commentary highlighted slowing growth and charges related to the Actio acquisition. These factors could limit enthusiasm despite the revenue beat.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.